[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100575111":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":29,"locations":36,"responsibleParty":53,"collaborators":55,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":12,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":12,"maxAge":12,"enrollmentInfo":66,"targetDuration":12,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":79,"whyStopped":12,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Centre hospitalier de l'Université de Montréal (CHUM)","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Standard of care","NO_INTERVENTION","Patients who had myocardial injury after noncardiac surgery are assigned to receive usual care.",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Systematic referral for secondary cardiovascular prevention","ACTIVE_COMPARATOR","Systematic referral to an internist within 6 weeks after myocardial injury after noncardiac surgery for implementation of secondary cardiovascular prevention strategies, individualized the patient's risk factors.",[18],"Procedure: Intervention Group",[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":12},"PROCEDURE","Intervention Group","Patients being referred to an internist or cardiologist after myocardial injury after noncardiac surgery",[14],[26],{"name":27,"affiliation":5,"role":28},"Emmanuelle Duceppe, MD PhD","PRINCIPAL_INVESTIGATOR",[30],{"name":31,"role":32,"phone":33,"phoneExt":34,"email":35},"Melodie Boko, MSc","CONTACT","514-890-8000","31541","synergy.dri.chum@ssss.gouv.qc.ca",[37],{"facility":38,"status":12,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Centre Hospitalier de l'Université de Montréal","Montreal","Quebec","H2X 0C1","Canada","CA",{"type":45,"coordinates":46},"Point",[47,48],-73.58781,45.50884,{"lat":48,"lon":47},[51],{"name":27,"role":32,"phone":33,"phoneExt":12,"email":52},"emmanuelle.duceppe.med@ssss.gouv.qc.ca",{"type":54,"investigatorFullName":12,"investigatorTitle":12,"investigatorAffiliation":12,"oldNameTitle":12,"oldOrganization":12},"SPONSOR",[56],{"name":57,"class":6},"Heart and Stroke Foundation of Canada","100575111","secondary-prevention-and-management-of-myocardial-injury-after-noncardiac-surgery-synergy-pilot-trial-100575111",false,"NCT06768034","SecondarY Prevention and maNagement of Myocardial Injury aftER Noncardiac surGerY (SYNERGY) Pilot Trial","A Pilot Pragmatic Randomized Controlled Trial Evaluating Secondary Cardiovascular Prevention Therapies in Patients Who Had a Myocardial Injury After Noncardiac Surgery to Prevent Major Cardiovascular Events","Inclusion Criteria:\n\n1. Have undergone noncardiac surgery,\n2. Had a myocardial injury after noncardiac surgery with a presumed ischemic mechanism and without an overt nonischemic precipitating etiology (e.g., sepsis)\n3. Provide written informed consent to participate in the SYNERGY pilot trial.\n\nExclusion Criteria:\n\n1. already on 2 of 3 secondary cardiovascular prevention medications (i.e., antiplatelet, statin, and\u002For angiotensin-converting enzyme inhibitor (ACEI)\u002Fangiotensin II receptor blocker (ARB)\n2. patients with contraindication to statins (i.e., decompensated or Child-Pugh C cirrhosis, acute liver failure, elevated AST\u002FALT greater than 2-fold the normal upper limit, previous demonstrated statin hypersensitivity, allergy, or statin-related myopathy);\n3. patients with contraindication to antiplatelet therapy (i.e., active or recent \\\u003C1-month peptic ulcer disease, esophageal or gastric variceal disease, history of intracranial or intraspinal hemorrhage, significant thrombocytopenia with platelet count \\\u003C50 × 109\u002FL),\n4. patients with contraindication to ACEI and ARB therapy (i.e, hypersensitivity or allergy to ACEI or ARB);\n5. Previously enrolled in the SYNERGY pilot trial,\n6. Considered unreliable or unable to complete the trial procedures.","ALL",{"count":67,"type":68},100,"ESTIMATED","INTERVENTIONAL",[71],"NA","Cardiac complications, particularly myocardial injury after noncardiac surgery (MINS), significantly contribute to 30-day mortality, affecting about 1 in 10 patients after noncardiac surgery. Despite its prevalence and serious implications, there is no consensus on managing myocardial injury after noncardiac surgery in clinical practice. Interventions commonly used for cardiovascular prevention in patients who had a heart attack outside of a surgery context could also be beneficial in patient with MINS. This pilot study trial aims to gather feasibility data, such as recruitment rates and intervention adherence that will guide on the design and inform on sample size of a future study with large pragmatic randomized controlled trial on the impact of systematic referral for secondary cardiovascular prevention on outcomes in patients who had a MINS.",[74],"Myocardial Injury After Noncardiac Surgery (MINS)",[76,77,78],"Noncardiac surgery","Secondary cardiovascular prevention","Randomized controlled trial","NOT_YET_RECRUITING","2026-03-17",{"date":82,"type":83},"2026-03-19","ACTUAL",{"date":85,"type":68},"2026-04",{"date":87,"type":68},"2027-11",{"name":5,"class":6},1]